Psyence Biomedical Ltd. (NASDAQ:PBM) Short Interest Up 71.1% in May

Posted by Latisha Jones on Jun 4th, 2026

Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report) saw a significant growth in short interest in May. As of May 15th, there was short interest totaling 71,272 shares, a growth of 71.1% from the April 30th total of 41,661 shares. Based on an average daily volume of 232,272 shares, the days-to-cover ratio is currently 0.3 days. Currently, 7.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Psyence Biomedical in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Psyence Biomedical has a consensus rating of “Sell”.

View Our Latest Stock Analysis on PBM

Institutional Trading of Psyence Biomedical

An institutional investor recently bought a new position in Psyence Biomedical stock. Virtu Financial LLC acquired a new stake in shares of Psyence Biomedical Ltd. (NASDAQ:PBM – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,325 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.55% of Psyence Biomedical at the end of the most recent quarter. Institutional investors own 77.44% of the company’s stock.

Psyence Biomedical Stock Performance

Shares of PBM opened at $3.95 on Thursday. The firm has a market cap of $4.03 million, a price-to-earnings ratio of 0.16 and a beta of 1.64. Psyence Biomedical has a fifty-two week low of $1.92 and a fifty-two week high of $74.94. The firm has a 50 day moving average price of $4.66 and a 200-day moving average price of $5.45.

Psyence Biomedical Company Profile

(Get Free Report)

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.